Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia ®

Otsuka Pharmaceutical Co., Ltd. announces that regulatory approval was received on January 19 for the manufacture and sale of Rexulti Tablets (generic name is brexpiprazole) in 1mg and 2 mg dosage sizes.® Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT and dopamine D receptors, and an antagonist at 5-HT and noradrenaline alpha receptors.1A22A1B/2C

The release as fetched from its publisher. otsuka.co.jp ↗